Dennis Manfred Krüger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dennis Manfred Krüger has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
- Andre Fischer
Department for Systems Medicine and Epigenetics, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany
5 shared publications - Tonatiuh Pena Centeno
Department for Systems Medicine and Epigenetics, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany
5 shared publications André Fischer
MBExC (Multi-Scale Bioimaging Excellence Cluster), Göttingen, Germany
3 shared publicationsB. Tillack
IHP, Im Technologiepark 25, D-15236 Frankfurt, Oder, Germany
3 shared publications- Farahnaz Sananbenesi
Research Group for Genome Dynamics in Brain Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany
3 shared publications - Monique M. B. Breteler
Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
3 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9404
Innervated human cardiac muscle model reveals sympathetic drivers of KCNH2-associated arrhythmias
Cardiac autonomic neurons regulate contractility. Autonomic nervous system dysregulation can cause sympathetic overdrive, leading to heart failure, and fatal arrhythmias. Here, we introduce innervated engineered human myocardium (iEHM), a model of neuro-cardiac junctions, constructed by fusing sympathetic neuronal organoids (SNO) and engineered human myocardium (EHM). Projections of sympathetic neurons formed presynaptic terminals in close proximity to cardiomyocytes and to the extensive vascular network co-developing in iEHM. Contractile responses to optogenetic stimulation of the accordingly engineered neuronal component demonstrated functional neuro-cardiac junctions. Modeling long-QT 2 in iEHM revealed sympathetic neuron hyperactivity and after depolarizations, underscoring a central role for sympathetic drive in KCNH2 -associated arrhythmias. β-adrenoreceptor blockade was insufficient to rescue the pro-arrhythmic phenotype, while mexiletine targeting both neurons and cardiomyocytes, proved to be more effective. Collectively, our data establishes iEHM as a New Approach Methodology that provides a human-relevant, physiologically integrated model for mechanistic investigations and pharmacological testing.
- 2 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9404
Open AccessInnervated human cardiac muscle model reveals sympathetic drivers of KCNH2-associated arrhythmias
Cardiac autonomic neurons regulate contractility. Autonomic nervous system dysregulation can cause sympathetic overdrive, leading to heart failure, and fatal arrhythmias. Here, we introduce innervated engineered human myocardium (iEHM), a model of neuro-cardiac junctions, constructed by fusing sympathetic neuronal organoids (SNO) and engineered human myocardium (EHM). Projections of sympathetic neurons formed presynaptic terminals in close proximity to cardiomyocytes and to the extensive vascular network co-developing in iEHM. Contractile responses to optogenetic stimulation of the accordingly engineered neuronal component demonstrated functional neuro-cardiac junctions. Modeling long-QT 2 in iEHM revealed sympathetic neuron hyperactivity and after depolarizations, underscoring a central role for sympathetic drive in KCNH2 -associated arrhythmias. β-adrenoreceptor blockade was insufficient to rescue the pro-arrhythmic phenotype, while mexiletine targeting both neurons and cardiomyocytes, proved to be more effective. Collectively, our data establishes iEHM as a New Approach Methodology that provides a human-relevant, physiologically integrated model for mechanistic investigations and pharmacological testing.
- Open Access
- 1 May 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (9) , 1-25
The role of microRNAs in executive functions: a comprehensive review and bioinformatics analysis of human and animal studies
Executive functions (EFs) are meta-cognitive abilities that orchestrate goal-directed behavior (i.e., set-shifting, working memory, and inhibitory control). Despite their strong genetic composition, the development of EFs is shaped by environmental exposures – as maternal distress, perinatal hypoxia, household dysfunction, neglection - which have varying degrees of impact depending on the duration or severity of the exposure, sensitive neurodevelopmental periods, and individual resiliency. Furthermore, they are negatively affected by aging and psychiatric, neurologic, and inflammatory diseases. MicroRNA dysregulation interferes with normal brain development and function and has been associated with various neuropsychiatric disorders; however, its effects on EFs remain unclear. Therefore, in this review we focus on the evidence regarding microRNA changes and their effects on EFs. We performed a systematic search from inception until October 2023 of four databases of human and animal studies. The results are presented narratively. Moreover, we conducted a bioinformatics analysis using experimental mRNA targets of the candidate microRNAs, as well as assessed the risk of bias of the included studies. We found 46 studies (23 in humans, 22 in animals, and one in both). The studies evaluated mild cognitive impairment, psychiatric disorders, and healthy aging. Gene mutations in MIR137 were associated with decreased EF performance, whereas MIR885 gene methylation was associated with increased executive functioning. Mutations in the genes of enzymes relevant for microRNA biosynthesis also impacted EFs. In the revised literature, the microRNAs that were consistently reported as dysregulated in two or more samples in relation to variations in EFs were miR-148a-3p for humans; miR-155, miR-30e, and miR-384-5p for rodents; and miR-132, miR-146a-5p, miR-148-3p, miR-181a-5p, miR-190b, miR-31, miR-501-3p, and miR-9-5p for both humans and rodents. The suggested regulatory pathways behind EFs included changes in neurogenesis, neurodevelopment, and synaptic plasticity/signaling. Changes in the various steps of microRNA biogenesis - such as mutations in the genes coding for microRNAs, reduced availability of relevant processing enzymes, or dysregulation of microRNA expression - are potentially associated with changes in EFs. Future research is required to better understand these associations in relation to developmental stage, diagnosis, disease severity, and the degree of the microRNA dysregulation.
- 1 May 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (9) , 1-25
Open AccessThe role of microRNAs in executive functions: a comprehensive review and bioinformatics analysis of human and animal studies
Executive functions (EFs) are meta-cognitive abilities that orchestrate goal-directed behavior (i.e., set-shifting, working memory, and inhibitory control). Despite their strong genetic composition, the development of EFs is shaped by environmental exposures – as maternal distress, perinatal hypoxia, household dysfunction, neglection - which have varying degrees of impact depending on the duration or severity of the exposure, sensitive neurodevelopmental periods, and individual resiliency. Furthermore, they are negatively affected by aging and psychiatric, neurologic, and inflammatory diseases. MicroRNA dysregulation interferes with normal brain development and function and has been associated with various neuropsychiatric disorders; however, its effects on EFs remain unclear. Therefore, in this review we focus on the evidence regarding microRNA changes and their effects on EFs. We performed a systematic search from inception until October 2023 of four databases of human and animal studies. The results are presented narratively. Moreover, we conducted a bioinformatics analysis using experimental mRNA targets of the candidate microRNAs, as well as assessed the risk of bias of the included studies. We found 46 studies (23 in humans, 22 in animals, and one in both). The studies evaluated mild cognitive impairment, psychiatric disorders, and healthy aging. Gene mutations in MIR137 were associated with decreased EF performance, whereas MIR885 gene methylation was associated with increased executive functioning. Mutations in the genes of enzymes relevant for microRNA biosynthesis also impacted EFs. In the revised literature, the microRNAs that were consistently reported as dysregulated in two or more samples in relation to variations in EFs were miR-148a-3p for humans; miR-155, miR-30e, and miR-384-5p for rodents; and miR-132, miR-146a-5p, miR-148-3p, miR-181a-5p, miR-190b, miR-31, miR-501-3p, and miR-9-5p for both humans and rodents. The suggested regulatory pathways behind EFs included changes in neurogenesis, neurodevelopment, and synaptic plasticity/signaling. Changes in the various steps of microRNA biogenesis - such as mutations in the genes coding for microRNAs, reduced availability of relevant processing enzymes, or dysregulation of microRNA expression - are potentially associated with changes in EFs. Future research is required to better understand these associations in relation to developmental stage, diagnosis, disease severity, and the degree of the microRNA dysregulation.
- Open Access
- 24 April 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (9) , 1-13
Blood-derived microRNA signatures associated with hippocampal structure and atrophy rate: findings from the Rhineland Study
MicroRNAs (miRNAs) have been linked to brain disorders, but their relations with hippocampal structure and atrophy remain unexplored. As the hippocampus is pivotal for cognition and dementia, understanding these relations and their specificity for the hippocampus would elucidate miRNA involvement in brain health and neurodegeneration. Here, using population-based data, we cross-sectionally and longitudinally examined the associations of blood-derived miRNAs with left and right hippocampal volume, hippocampal asymmetry, and total brain volume. Expression of miRNAs and their putative target genes was measured at study baseline in whole blood using RNA sequencing. Brain imaging measures were examined at baseline and re-examined 4.60–8.02 years later using 3 T MRI. We investigated miRNA associations with imaging measures cross-sectionally using linear regression and longitudinally using linear mixed-effect models. Cross-sectionally, six miRNAs (miR-199a-3p, miR-199b-3p, miR-155-5p, miR-146a-5p, miR-6859-5p, miR-505-5p) were associated exclusively with left hippocampal volume. Longitudinally, another five miRNAs (miR-361-3p, miR-4473, miR-381-3p, miR-543, miR-370-3p) were associated with left hippocampal, right hippocampal, and total brain atrophy rates. Twenty-one miRNAs were exclusively associated with total brain atrophy rate. In whole blood, miRNAs identified in the cross-sectional analysis targeted genes related to brain development, memory, and synapse assembly. MiRNAs from the longitudinal analysis targeted genes related to axonal and dendritic growth. Several identified miRNAs were previously linked to neurodegeneration. Especially miR-146a-5p and miR-370-3p have been consistently linked to dementia and could be investigated as presymptomatic blood-based biomarkers. The brain-specific functions and interactions with target genes of identified miRNAs could be further investigated to develop therapeutic strategies against neurodegeneration.
- 24 April 2026
- Published by Springer Nature in Molecular Psychiatry
- Vol. 31 (9) , 1-13
Open AccessBlood-derived microRNA signatures associated with hippocampal structure and atrophy rate: findings from the Rhineland Study
MicroRNAs (miRNAs) have been linked to brain disorders, but their relations with hippocampal structure and atrophy remain unexplored. As the hippocampus is pivotal for cognition and dementia, understanding these relations and their specificity for the hippocampus would elucidate miRNA involvement in brain health and neurodegeneration. Here, using population-based data, we cross-sectionally and longitudinally examined the associations of blood-derived miRNAs with left and right hippocampal volume, hippocampal asymmetry, and total brain volume. Expression of miRNAs and their putative target genes was measured at study baseline in whole blood using RNA sequencing. Brain imaging measures were examined at baseline and re-examined 4.60–8.02 years later using 3 T MRI. We investigated miRNA associations with imaging measures cross-sectionally using linear regression and longitudinally using linear mixed-effect models. Cross-sectionally, six miRNAs (miR-199a-3p, miR-199b-3p, miR-155-5p, miR-146a-5p, miR-6859-5p, miR-505-5p) were associated exclusively with left hippocampal volume. Longitudinally, another five miRNAs (miR-361-3p, miR-4473, miR-381-3p, miR-543, miR-370-3p) were associated with left hippocampal, right hippocampal, and total brain atrophy rates. Twenty-one miRNAs were exclusively associated with total brain atrophy rate. In whole blood, miRNAs identified in the cross-sectional analysis targeted genes related to brain development, memory, and synapse assembly. MiRNAs from the longitudinal analysis targeted genes related to axonal and dendritic growth. Several identified miRNAs were previously linked to neurodegeneration. Especially miR-146a-5p and miR-370-3p have been consistently linked to dementia and could be investigated as presymptomatic blood-based biomarkers. The brain-specific functions and interactions with target genes of identified miRNAs could be further investigated to develop therapeutic strategies against neurodegeneration.
- Open Access
- 12 June 2025
- Published by MDPI AG in Non-Coding RNA
- Vol. 11 (3) , 45
Role of Compensatory miRNA Networks in Cognitive Recovery from Heart Failure
Background: Heart failure (HF) is associated with an increased risk of cognitive impairment and hippocampal dysfunction, yet the underlying molecular mechanisms remain poorly understood. This study aims to investigate the role of microRNA (miRNA) networks in hippocampus-dependent memory recovery in a mouse model of HF. Methods: CaMKIIδC transgenic (TG) mice, a model for HF, were used to assess hippocampal function at 3 and 6 months of age. Memory performance was evaluated using hippocampus-dependent behavioral tasks. Small RNA sequencing was performed to analyze hippocampal miRNA expression profiles across both time points. Bioinformatic analyses identified miRNAs that potentially regulate genes previously implicated in HF-induced cognitive impairment. Results: We have previously shown that at 3 months of age, CaMKIIδC TG mice exhibited significant memory deficits associated with dysregulated hippocampal gene expression. In this study, we showed that these impairments, memory impairment and hippocampal gene expression, were no longer detectable at 6 months, despite persistent cardiac dysfunction. However, small RNA sequencing revealed a dynamic shift in hippocampal miRNA expression, identifying 27 miRNAs as “compensatory miRs” that targeted 73% of the transcripts dysregulated at 3 months but reinstated by 6 months. Notably, miR-181a-5p emerged as a central regulatory hub, with its downregulation coinciding with restored memory function. Conclusions: These findings suggest that miRNA networks contribute to the restoration of hippocampal function in HF despite continued cardiac pathology and provide an important compensatory mechanism towards memory impairment. A better understanding of these compensatory miRNA mechanisms may provide novel therapeutic targets for managing HF-related cognitive dysfunction.
- 12 June 2025
- Published by MDPI AG in Non-Coding RNA
- Vol. 11 (3) , 45
Open AccessRole of Compensatory miRNA Networks in Cognitive Recovery from Heart Failure
Background: Heart failure (HF) is associated with an increased risk of cognitive impairment and hippocampal dysfunction, yet the underlying molecular mechanisms remain poorly understood. This study aims to investigate the role of microRNA (miRNA) networks in hippocampus-dependent memory recovery in a mouse model of HF. Methods: CaMKIIδC transgenic (TG) mice, a model for HF, were used to assess hippocampal function at 3 and 6 months of age. Memory performance was evaluated using hippocampus-dependent behavioral tasks. Small RNA sequencing was performed to analyze hippocampal miRNA expression profiles across both time points. Bioinformatic analyses identified miRNAs that potentially regulate genes previously implicated in HF-induced cognitive impairment. Results: We have previously shown that at 3 months of age, CaMKIIδC TG mice exhibited significant memory deficits associated with dysregulated hippocampal gene expression. In this study, we showed that these impairments, memory impairment and hippocampal gene expression, were no longer detectable at 6 months, despite persistent cardiac dysfunction. However, small RNA sequencing revealed a dynamic shift in hippocampal miRNA expression, identifying 27 miRNAs as “compensatory miRs” that targeted 73% of the transcripts dysregulated at 3 months but reinstated by 6 months. Notably, miR-181a-5p emerged as a central regulatory hub, with its downregulation coinciding with restored memory function. Conclusions: These findings suggest that miRNA networks contribute to the restoration of hippocampal function in HF despite continued cardiac pathology and provide an important compensatory mechanism towards memory impairment. A better understanding of these compensatory miRNA mechanisms may provide novel therapeutic targets for managing HF-related cognitive dysfunction.
- 23 April 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4364-4383
Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders
Micro RNAs (miRNAs) play a crucial role as regulators of various biological processes and have been implicated in the pathogenesis of mental disorders such as schizophrenia and bipolar disorders. In this study, we investigate the expression patterns of miRNAs in the PsyCourse Study (n = 1786), contrasting three broad diagnostic groups: Psychotic (Schizophrenia-spectrum disorders), Affective (Bipolar Disorder I, II and recurrent Depression), and neurotypic healthy individuals. Through comprehensive analyses, including differential miRNA expression, miRNA transcriptome-wide association study (TWAS), and predictive modelling, we identified multiple miRNAs unique to Psychotic and Affective groups as well as shared by both. Furthermore, we performed integrative analysis to identify the target genes of the dysregulated miRNAs and elucidate their potential roles in psychosis. Our findings reveal significant alterations of multiple miRNAs such as miR-584-3p and miR-99b-5p across the studied diagnostic groups, highlighting their role as molecular correlates. Additionally, the miRNA TWAS analysis discovered previously known and novel genetically dysregulated miRNAs confirming the relevance in the etiology of the diagnostic groups. Importantly, novel factors and putative molecular mechanisms underlying these groups were uncovered through the integration of miRNA-target gene interactions. This comprehensive investigation provides valuable insights into the molecular underpinnings of severe mental disorders, shedding light on the complex regulatory networks involving miRNAs.
- 23 April 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (9) , 4364-4383
Integrative analysis of miRNA expression profiles reveals distinct and common molecular mechanisms underlying broad diagnostic groups of severe mental disorders
Micro RNAs (miRNAs) play a crucial role as regulators of various biological processes and have been implicated in the pathogenesis of mental disorders such as schizophrenia and bipolar disorders. In this study, we investigate the expression patterns of miRNAs in the PsyCourse Study (n = 1786), contrasting three broad diagnostic groups: Psychotic (Schizophrenia-spectrum disorders), Affective (Bipolar Disorder I, II and recurrent Depression), and neurotypic healthy individuals. Through comprehensive analyses, including differential miRNA expression, miRNA transcriptome-wide association study (TWAS), and predictive modelling, we identified multiple miRNAs unique to Psychotic and Affective groups as well as shared by both. Furthermore, we performed integrative analysis to identify the target genes of the dysregulated miRNAs and elucidate their potential roles in psychosis. Our findings reveal significant alterations of multiple miRNAs such as miR-584-3p and miR-99b-5p across the studied diagnostic groups, highlighting their role as molecular correlates. Additionally, the miRNA TWAS analysis discovered previously known and novel genetically dysregulated miRNAs confirming the relevance in the etiology of the diagnostic groups. Importantly, novel factors and putative molecular mechanisms underlying these groups were uncovered through the integration of miRNA-target gene interactions. This comprehensive investigation provides valuable insights into the molecular underpinnings of severe mental disorders, shedding light on the complex regulatory networks involving miRNAs.
- Open Access
- 11 April 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
A role for astrocytic miR-129-5p in frontotemporal dementia
Frontotemporal dementia is a debilitating neurodegenerative disorder characterized by frontal and temporal lobe degeneration, resulting in behavioral changes, language difficulties, and cognitive decline. In this study, smallRNA sequencing was conducted on postmortem brain tissues obtained from the frontal and temporal of FTD patients with GRN, MAPT, or C9ORF72 mutations. Our analysis identified miR-129-5p as consistently deregulated across all analyzed mutation conditions and brain regions. Functional investigations in in-vitro models revealed a novel role of miR-129-5p in astrocytes, where its loss led to neuroinflammation and impaired neuronal support functions, including reduced glutamate uptake. Depletion of miR-129-5p in astrocytes also resulted in the loss of neuronal spines and altered neuronal network activity in a cell culture system. These findings highlight miR-129-5p as a potential therapeutic target in neurodegenerative diseases and also sheds light on the role of astrocytes in Frontotemporal dementia pathogenesis.
- 11 April 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-14
Open AccessA role for astrocytic miR-129-5p in frontotemporal dementia
Frontotemporal dementia is a debilitating neurodegenerative disorder characterized by frontal and temporal lobe degeneration, resulting in behavioral changes, language difficulties, and cognitive decline. In this study, smallRNA sequencing was conducted on postmortem brain tissues obtained from the frontal and temporal of FTD patients with GRN, MAPT, or C9ORF72 mutations. Our analysis identified miR-129-5p as consistently deregulated across all analyzed mutation conditions and brain regions. Functional investigations in in-vitro models revealed a novel role of miR-129-5p in astrocytes, where its loss led to neuroinflammation and impaired neuronal support functions, including reduced glutamate uptake. Depletion of miR-129-5p in astrocytes also resulted in the loss of neuronal spines and altered neuronal network activity in a cell culture system. These findings highlight miR-129-5p as a potential therapeutic target in neurodegenerative diseases and also sheds light on the role of astrocytes in Frontotemporal dementia pathogenesis.
- Top Cited PapersOpen Access
- 29 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8054) , 503-511
Engineered heart muscle allografts for heart repair in primates and humans
Cardiomyocytes can be implanted to remuscularize the failing heart1–7. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques. After confirmation of in vitro and in vivo (nude rat model) equivalence of the newly developed rhesus macaque EHM model with a previously established Good Manufacturing Practice-compatible human EHM formulation8, long-term retention (up to 6 months) and dose-dependent enhancement of the target heart wall by EHM grafts constructed from 40 to 200 million cardiomyocytes/stromal cells were demonstrated in macaques with and without myocardial infarction-induced heart failure. In the heart failure model, evidence for EHM allograft-enhanced target heart wall contractility and ejection fraction, which are measures for local and global heart support, was obtained. Histopathological and gadolinium-based perfusion magnetic resonance imaging analyses confirmed cell retention and functional vascularization. Arrhythmia and tumour growth were not observed. The obtained feasibility, safety and efficacy data provided the pivotal underpinnings for the approval of a first-in-human clinical trial on tissue-engineered heart repair. Our clinical data confirmed remuscularization by EHM implantation in a patient with advanced heart failure.
- 29 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8054) , 503-511
Top Cited PapersOpen AccessEngineered heart muscle allografts for heart repair in primates and humans
Cardiomyocytes can be implanted to remuscularize the failing heart1–7. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques. After confirmation of in vitro and in vivo (nude rat model) equivalence of the newly developed rhesus macaque EHM model with a previously established Good Manufacturing Practice-compatible human EHM formulation8, long-term retention (up to 6 months) and dose-dependent enhancement of the target heart wall by EHM grafts constructed from 40 to 200 million cardiomyocytes/stromal cells were demonstrated in macaques with and without myocardial infarction-induced heart failure. In the heart failure model, evidence for EHM allograft-enhanced target heart wall contractility and ejection fraction, which are measures for local and global heart support, was obtained. Histopathological and gadolinium-based perfusion magnetic resonance imaging analyses confirmed cell retention and functional vascularization. Arrhythmia and tumour growth were not observed. The obtained feasibility, safety and efficacy data provided the pivotal underpinnings for the approval of a first-in-human clinical trial on tissue-engineered heart repair. Our clinical data confirmed remuscularization by EHM implantation in a patient with advanced heart failure.
- Open Access
- 9 January 2025
- Published by MDPI AG in Non-Coding RNA
- Vol. 11 (1) , 2
LncRNA 3222401L13Rik Is Upregulated in Aging Astrocytes and Regulates Neuronal Support Function Through Interaction with Npas3
Aging leads to cognitive decline and increased risk of neurodegenerative diseases. While molecular changes in central nervous system (CNS) cells contribute to this decline, the mechanisms are not fully understood. Long non-coding RNAs (lncRNAs) are key regulators of cellular functions. Background/Objectives: The roles of lncRNAs in aging, especially in glial cells, are not well characterized. Methods: We investigated lncRNA expression in non-neuronal cells from aged mice and identified 3222401L13Rik, a previously unstudied lncRNA, as upregulated in astrocytes during aging. Results: Knockdown of 3222401L13Rik in primary astrocytes revealed its critical role in regulating genes for neuronal support and synapse organization, a function conserved in human iPSC-derived astrocytes. A 3222401L13Rik interacts with the transcription factor Neuronal PAS Domain Protein 3 (Npas3), and overexpression of Npas3 rescues deficits in astrocytes lacking 3222401L13Rik. Conclusions: These data suggest that 3222401L13Rik upregulation may help delay age-related cognitive decline.
- 9 January 2025
- Published by MDPI AG in Non-Coding RNA
- Vol. 11 (1) , 2
Open AccessLncRNA 3222401L13Rik Is Upregulated in Aging Astrocytes and Regulates Neuronal Support Function Through Interaction with Npas3
Aging leads to cognitive decline and increased risk of neurodegenerative diseases. While molecular changes in central nervous system (CNS) cells contribute to this decline, the mechanisms are not fully understood. Long non-coding RNAs (lncRNAs) are key regulators of cellular functions. Background/Objectives: The roles of lncRNAs in aging, especially in glial cells, are not well characterized. Methods: We investigated lncRNA expression in non-neuronal cells from aged mice and identified 3222401L13Rik, a previously unstudied lncRNA, as upregulated in astrocytes during aging. Results: Knockdown of 3222401L13Rik in primary astrocytes revealed its critical role in regulating genes for neuronal support and synapse organization, a function conserved in human iPSC-derived astrocytes. A 3222401L13Rik interacts with the transcription factor Neuronal PAS Domain Protein 3 (Npas3), and overexpression of Npas3 rescues deficits in astrocytes lacking 3222401L13Rik. Conclusions: These data suggest that 3222401L13Rik upregulation may help delay age-related cognitive decline.
- Open Access
- 29 August 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (10) , 7138-7159
Blood‐derived microRNAs are related to cognitive domains in the general population
INTRODUCTION: Blood‐derived microRNAs (miRNAs) are potential candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel miRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking.METHODS: We examined blood‐derived miRNAs and miRNA co‐expression clusters in relation to cognitive domains, structural magnetic resonance imaging measures, target gene expression, and genetic variants in 2869 participants of a population‐based cohort.RESULTS: Five previously identified and 14 novel miRNAs were associated with cognitive domains. Eleven of these were also associated with cortical thickness and two with hippocampal volume. Multi‐omics analysis showed that certain identified miRNAs were genetically influenced and regulated genes in pathways like neurogenesis and synapse assembly.DISCUSSION: We identified miRNAs associated with cognitive domains, brain regions, and neuronal processes affected by aging and neurodegeneration, making them promising candidate blood‐based biomarkers or therapeutic targets of subclinical cognitive dysfunction.Highlights: We investigated the association of blood‐derived microRNAs with cognitive domains. Five previously identified and 14 novel microRNAs were associated with cognition. Eleven cognition‐related microRNAs were also associated with cortical thickness. Identified microRNAs were linked to genes associated with neuronal functions. Results provide putative biomarkers or therapeutic targets of cognitive aging.
- 29 August 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (10) , 7138-7159
Open AccessBlood‐derived microRNAs are related to cognitive domains in the general population
INTRODUCTION: Blood‐derived microRNAs (miRNAs) are potential candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel miRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking.METHODS: We examined blood‐derived miRNAs and miRNA co‐expression clusters in relation to cognitive domains, structural magnetic resonance imaging measures, target gene expression, and genetic variants in 2869 participants of a population‐based cohort.RESULTS: Five previously identified and 14 novel miRNAs were associated with cognitive domains. Eleven of these were also associated with cortical thickness and two with hippocampal volume. Multi‐omics analysis showed that certain identified miRNAs were genetically influenced and regulated genes in pathways like neurogenesis and synapse assembly.DISCUSSION: We identified miRNAs associated with cognitive domains, brain regions, and neuronal processes affected by aging and neurodegeneration, making them promising candidate blood‐based biomarkers or therapeutic targets of subclinical cognitive dysfunction.Highlights: We investigated the association of blood‐derived microRNAs with cognitive domains. Five previously identified and 14 novel microRNAs were associated with cognition. Eleven cognition‐related microRNAs were also associated with cortical thickness. Identified microRNAs were linked to genes associated with neuronal functions. Results provide putative biomarkers or therapeutic targets of cognitive aging.
- Open Access
Circulating microRNAs are related to cognitive domains in the general population
INTRODUCTION: Circulating microRNAs have been suggested as candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel microRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking. METHODS: We examined circulating microRNAs and microRNA co-expression clusters in relation to cognitive domains, structural MRI measures, and target gene expression in 2869 participants of a population-based cohort. RESULTS: Five previously identified and 10 novel microRNAs were associated with cognitive domains. Importantly, seven of these microRNAs were also associated with cortical thickness and two with hippocampal volume. Functional genomics analysis showed that the identified microRNAs regulated genes in pathways like neurogenesis, axon guidance, and synapse assembly. DISCUSSION: We identified microRNAs associated with cognitive domains, brain regions, and neuronal processes affected by aging and neurodegeneration, making them promising candidate blood-based biomarkers or therapeutic targets of subclinical cognitive dysfunction.
Open AccessCirculating microRNAs are related to cognitive domains in the general population
INTRODUCTION: Circulating microRNAs have been suggested as candidates for detecting and preventing subclinical cognitive dysfunction. However, replication of previous findings and identification of novel microRNAs associated with cognitive domains, including their relation to brain structure and the pathways they regulate, are still lacking. METHODS: We examined circulating microRNAs and microRNA co-expression clusters in relation to cognitive domains, structural MRI measures, and target gene expression in 2869 participants of a population-based cohort. RESULTS: Five previously identified and 10 novel microRNAs were associated with cognitive domains. Importantly, seven of these microRNAs were also associated with cortical thickness and two with hippocampal volume. Functional genomics analysis showed that the identified microRNAs regulated genes in pathways like neurogenesis, axon guidance, and synapse assembly. DISCUSSION: We identified microRNAs associated with cognitive domains, brain regions, and neuronal processes affected by aging and neurodegeneration, making them promising candidate blood-based biomarkers or therapeutic targets of subclinical cognitive dysfunction.